Main Article Content
Abstract
Acute thromboembolic disorders are emerged to be one of the main causes of worldwidemortality. Themanagement of disorder can be solve by new generationthrombolytic therapy. This disorder cause by the failure to produce bodily clot lysins molecules such as tissue plasminogen activator (t-PA) and Urokinase.The global expansion, scientific and technological advantages lead the possibility for the production andclinical intervention administration of thrombolytic agents constitute t-PA, Urokinase, recombinant tissue plasminogen activator (rt-PA) and recombinant single chain Urokinase plasminogen activator (rscu-PA) to cure these disorders.